Hip ReplacementNCT04989998
Patient Outcomes Using HIP7 Software as Compared to Conventional THA
A study testing Hip7 Software on Kick/ CORI platforms and Conventional surgical procedures in people with Hip Replacement, run by Smith & Nephew Orthopaedics AG.
Trial summary
The study is designed to demonstrate how Hip7 software can lead to improved patient outcomes compared to conventional procedures with standard instrumentation for total hip arthroplasties (THA) surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Replacement
- What is being tested?
- Hip7 Software on Kick/ CORI platforms and Conventional surgical procedures
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 30 Sep 2021to 31 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The subject or legal guardian must provide written informed consent (reference section 7.5).
- Subjects eighteen (18) years or older and considered skeletally mature.
- Willing and able to make all required study visits.
- Able to follow instructions and deemed capable of completing the FJS, OHS, HOOS and EQ-5D-5L questionnaires.
- Subject requires a THA as a primary indication.
- Subject is a suitable candidate for implanting specific S+N implant system in the investigator's judgement.
Show all 9Show fewer
- Subject agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the Ethics Committee (EC) approved informed consent form.
- Subject plans to be available through 12 months postoperative follow-up
- Routine radiographic assessment including CT and X-ray is possible.
Who cannot join
- Contraindicated for robotic THA or POLAR3 hip implant.
- Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1, or during the study.
- Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
- Any subject that meets the definition of a Vulnerable Subject per International Organization for Standardization (ISO) 14155:2011 Section 3.44.
- Subjects who have participated previously in this trial through THA on their other hip.
- Subjects with a history of poor compliance with medical treatment (i.e have mental illness, drug or alcohol addiction).
Show all 16Show fewer
- Subjects who need a THA procedure on the index joint as a revision for a previously failed surgery.
- Subjects suspected to need bilateral surgery in the next 12 months.
- Subject has received THA on the opposing hip within the previous 6 months.
- Subjects not understanding the language used in the Informed Consent Form.
- Subjects with an active infection or sepsis (treated or untreated).
- Subjects morbidly obese with a BMI greater than 40.
- Subjects in the opinion of the Investigator, has advanced osteoarthritis or joint disease at the time of surgery and are better suited for an alternate procedure.
- Subjects that have condition(s) that may interfere with the THA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease, or an active, local infection).
- Subjects, in the opinion of the Investigator, has a neuromuscular disorder that prohibited control of the index joint.
- Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
About this study
Official title: A Prospective, Multi-center, Randomized Controlled Study to Evaluate Patient Outcomes Using Hip7 Software as Compared to Conventional Surgical Technique in S+N Total Hip Arthroplasties (THA)
The study is designed to demonstrate how Hip7 software can lead to improved patient outcomes compared to conventional procedures with standard instrumentation for total hip arthroplasties (THA) surgery.
Read the detailed description
This study is a prospective, multi-center, randomized, controlled clinical study in total hip arthroplasties (THA) surgery. The subjects meeting the inclusion/exclusion criteria specified in the protocol will receive THA using either Hip7 software or conventional instrumentation.
The clinical follow-up evaluation will be performed preoperatively (Baseline), operatively, 6 weeks, 6 and 12 months after surgery using patient reported outcome measures regarding their general health, hip and physical abilities, quality of life and pain level.
- Conditions
- Hip Replacement
- Being tested
- Hip7 Software on Kick/ CORI platforms, Conventional surgical procedures
- Keywords
- HIP7, Total Hip Arthroplasties (THA)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hip7 Software on Kick/ CORI platformsDevice
Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
Conventional surgical proceduresDevice
THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
| Study group | Role | What they receive |
|---|---|---|
| Hip7 Software on Kick/ CORI platforms | Experimental | Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants. Receives: Device: Hip7 Software on Kick/ CORI platforms |
| Conventional procedures with standard, manual instrumentation and digital templating techniques | Active comparator | Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants. Receives: Device: Conventional surgical procedures |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forgotten Joint Score (FJS)
Compare Forgotten Joint Score (FJS) utilizing Hip7 software on Kick \& CORI platforms with POLAR3 system to conventional procedures with standard instrumentation and digital templating techniques at 12 months post-operation. The FJS-12 Questionnaire comprises measures for assessment of joint-specific patient reported outcomes that focuses on subject's awareness of replaced joint in everyday life. Joint awareness defined as any unintended perception of a joint. Subjects rate awareness of their hip arthroplasty in 12 questions with a 5-point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". Scores are summed \& linearly transformed in a 0-100 scale with a high value reflecting subject's ability to forget the replaced hip joint during daily living activities.
Measured: 12 months post-surgery
Secondary outcomes (8)
Change in Frequency of Reduction of Outliers
Frequency of reduction of outliers* with Hip7 software as compared to conventional procedures (as defined by literature) using digital templating techniques for posterior and direct anterior approaches
*Outliers are defined as acetabular component placement outside the desired "safe zone". Two most commonly used safe zones are described by Lewinnek and Callanan with the inclination and anteversion values outlined below: Callanan Safe Zone -- Anteversion between 5-25 degrees, Inclination between 30-45 degrees. Lewinnek - Anteversion between 5-25 degrees, Inclination between 30-50 degrees [i.e. 40° ± 10° and 15° ± 10°].
Measured: 6 weeks post surgery
Patient Reported Outcomes: Hip Disability and Osteoarthritis Outcome Score (HOOS)
The HOOS is developed as an instrument to assess the subject's opinion about their hip and associated problems. HOOS consists of 5 subscales: Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and hip related QOL. The last week is taken into consideration when answering the questions. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
Measured: 12 months post-surgery
Patient Reported Outcomes: Oxford Hip Score (OHS)
The OHS is a 12-item questionnaire for patients who undergo total hip replacement (THR) to complete. Patients are asked to reflect on their pain and functional ability over the previous four weeks. There are two domains (pain and function) with six items or questions in each. Each item has four possible responses. Responses were from 1 = least difficult to 4= most difficult. Item scores are summed to give a total score from anywhere between 0 and 48. The lower the score, the better the outcome.
Measured: 12 months post-surgery
Patient Reported Outcomes: EuroQol (European Quality of Life) five-dimensional Five-level (EQ-5D-5L)
The EQ-5D-5L questionnaire consists of two parts. Part one is the descriptive system to describe the subject's health state and consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The subject indicates their health state by marking the most appropriate statement in each of the 5 areas. Responses are converted to scores ranging from less than 0 to 1.0 with high scores representing higher health utility. Part two is the EQ Visual Analog Scale (VAS) that records the subject's self-rated health on a vertical visual analogue scale. Scale ranges from 0-100 with 100 labelled "The best health you can imagine" and 0 "The worst health you can imagine".
Measured: 12 months post-surgery
Cup placement accuracy
To demonstrate cup placement accuracy (defined as the difference between inclination, anteversion, leg length, and offset target) from the Computerized Tomography [CT]).
Measured: 6 weeks post-op
Assess Pelvic Tilt at 6 Weeks
A CT scan will assess pelvic tilt (angle of pelvic bone in relation to spine and femur)
Measured: 6 weeks post-op
Assess Range of Motion of Femur at 6 Weeks
Medical staff will measure angles of femur movement in order to assess active range of motion. Active range of motion measures include angles of active flexion, abduction, adduction, external rotation and internal rotation.
Measured: 6 weeks post-op
Assess Frequency of Femur Head Dislocation at 6 Weeks
Whether the subject experienced femoral head dislocation will be assessed at 6 weeks post op. Femoral head dislocation will be determined based on the count of participants with joint dislocation responses recorded by the investigator in the Adverse Events Case Report Form (CRF).
Measured: 6 weeks post-op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2021
- Study start30 Sep 2021 (estimated)
- Primary completion31 Oct 2024 (estimated)
- Study completion31 Oct 2024 (estimated)
Why it stopped: update to marketing strategy for hip robotics and related instrumentation
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip ReplacementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Smith & Nephew Orthopaedics AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Edward T Davis, MB ChB, M.Sc, PGCME, FRCS(T&O), Principal investigator, The Royal Orthopaedic Hospital NHS Foundation TrustYixin Zhou, Principal investigator, Beijing Jishuitan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04989998
- Sponsor's protocol ID
- HIP7.2020.10
- Status last verified
- Jul 2022
- First submitted
- 28 Jun 2021
- Last updated
- 29 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multi-center, Randomized Controlled Study to Evaluate Patient Outcomes Using Hip7 Software as Compared to Conventional Surgical Technique in S+N Total Hip Arthroplasties (THA)
- ClinicalTrials.gov ID
- NCT04989998
- Acronym / sponsor ID
- HIP7.2020.10
- Conditions
- Hip Replacement
- Keywords
- HIP7, Total Hip Arthroplasties (THA)
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: update to marketing strategy for hip robotics and related instrumentation
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Smith & Nephew Orthopaedics AGIndustry (pharma, biotech, devices)
- Study start
- 30 Sep 2021 (estimated)
- Primary completion
- 31 Oct 2024 (estimated)
- Study completion
- 31 Oct 2024 (estimated)
- First posted
- 4 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is designed to demonstrate how Hip7 software can lead to improved patient outcomes compared to conventional procedures with standard instrumentation for total hip arthroplasties (THA) surgery.
Detailed description
This study is a prospective, multi-center, randomized, controlled clinical study in total hip arthroplasties (THA) surgery. The subjects meeting the inclusion/exclusion criteria specified in the protocol will receive THA using either Hip7 software or conventional instrumentation.
The clinical follow-up evaluation will be performed preoperatively (Baseline), operatively, 6 weeks, 6 and 12 months after surgery using patient reported outcome measures regarding their general health, hip and physical abilities, quality of life and pain level.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hip7 Software on Kick/ CORI platforms | Experimental | Device: Hip7 Software on Kick/ CORI platformsSubjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants. |
| Conventional procedures with standard, manual instrumentation and digital templating techniques | Active comparator | Device: Conventional surgical proceduresSubjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- The subject or legal guardian must provide written informed consent (reference section 7.5).
- Subjects eighteen (18) years or older and considered skeletally mature.
- Willing and able to make all required study visits.
- Able to follow instructions and deemed capable of completing the FJS, OHS, HOOS and EQ-5D-5L questionnaires.
- Subject requires a THA as a primary indication.
Key exclusion criteria (16 listed)
- Contraindicated for robotic THA or POLAR3 hip implant.
- Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1, or during the study.
- Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
- Any subject that meets the definition of a Vulnerable Subject per International Organization for Standardization (ISO) 14155:2011 Section 3.44.
- Subjects who have participated previously in this trial through THA on their other hip.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hip7 Software on Kick/ CORI platformsTotal hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants. | Device | Hip7 Software on Kick/ CORI platforms |
| Conventional surgical proceduresTHA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants. | Device | Conventional procedures with standard, manual instrumentation and digital templating techniques |
Primary outcome
Forgotten Joint Score (FJS)
Time frame: 12 months post-surgery
Compare Forgotten Joint Score (FJS) utilizing Hip7 software on Kick \& CORI platforms with POLAR3 system to conventional procedures with standard instrumentation and digital templating techniques at 12 months post-operation. The FJS-12 Questionnaire comprises measures for assessment of joint-specific patient reported outcomes that focuses on subject's awareness of replaced joint in everyday life. Joint awareness defined as any unintended perception of a joint. Subjects rate awareness of their hip arthroplasty in 12 questions with a 5-point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". Scores are summed \& linearly transformed in a 0-100 scale with a high value reflecting subject's ability to forget the replaced hip joint during daily living activities.
8 secondary outcomes
Change in Frequency of Reduction of Outliers
Time frame: 6 weeks post surgery
Patient Reported Outcomes: Hip Disability and Osteoarthritis Outcome Score (HOOS)
Time frame: 12 months post-surgery
Patient Reported Outcomes: Oxford Hip Score (OHS)
Time frame: 12 months post-surgery
Patient Reported Outcomes: EuroQol (European Quality of Life) five-dimensional Five-level (EQ-5D-5L)
Time frame: 12 months post-surgery
Cup placement accuracy
Time frame: 6 weeks post-op
Assess Pelvic Tilt at 6 Weeks
Time frame: 6 weeks post-op
Assess Range of Motion of Femur at 6 Weeks
Time frame: 6 weeks post-op
Assess Frequency of Femur Head Dislocation at 6 Weeks
Time frame: 6 weeks post-op
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2022.
- Individual participant dataSharing planned: No
Related trials for Hip Replacement
RecruitingObservational study
The restor3d Outcomes Registry
Joint Replacement, Arthropathy
RecruitingPhase 4
Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty
Pain, Postoperative, Muscle Weakness
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Not yet recruitingObservational study
Preoperative Muscle Stiffness, Functional Reserve, and Postoperative Quality of Recovery in Lower Extremity Arthroplasty
Osteoarthritis (Knee / Hip), Sarcopenia
Not yet recruitingObservational study
Carotid Ultrasound for Post-Spinal Anesthesia Hypotension in Elderly Hip Surgery
Hypotension After Spinal Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Edward T Davis, MB ChB, M.Sc, PGCME, FRCS(T&O) principal investigator
The Royal Orthopaedic Hospital NHS Foundation Trust
Yixin Zhou principal investigator
Beijing Jishuitan Hospital
Questions about this trial
What is this clinical trial studying?
A study testing Hip7 Software on Kick/ CORI platforms and Conventional surgical procedures in people with Hip Replacement, run by Smith & Nephew Orthopaedics AG.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 29 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forgotten Joint Score (FJS) (time frame: 12 months post-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2022.